Journal of the American Medical Directors Association · Oct 12, 2025

Cardiovascular Safety of Dipeptidyl Peptidase 4 Inhibitors Compared With Insulin or Sulfonylureas Added to Metformin Among Older People With Diabetes Living in Long-Term Care Facilities

By Wondimkun YA, Caughey GE, Inacio MC et al.

OBJECTIVES: To examine the cardiovascular safety of dipeptidyl peptidase 4 (DPP-4) inhibitors compared with long-acting insulin or sulfonylurea initiation added to metformin in older people with diabetes in long-term care facilities (LTCFs). DESIGN: A new-user multiple active comparator retrospective cohort study of the cardiovascular safety of DPP-4 inhibitors compared with long-acting insulin and sulfonylureas when added to metformin. SETTING AND PARTICIPANTS: Individuals aged ≥65 years with diabetes who entered LTCFs between January 1, 2009, and December 31, 2018, were included within the Registry of Senior Australians National Historical cohort. METHODS: Time to hospitalization for heart failure or major adverse cardiovascular events (MACEs) (a composite of nonfatal stroke, nonfatal myocardial infarction or cardiovascular mortality) over a 5-year follow-up period was compared between matched DPP-4 inhibitors and long-acting insulin or sulfonylurea users. Fine-Gray models were used to estimate subdistribution hazard ratios (sHRs). RESULTS: Among initiators of DPP-4 inhibitors compared with insulin (n = 4414), the risk of hospitalization for heart failure was 0.98 (95% CI, 0.77-1.25), whereas the risk of MACEs was 0.95 (95% CI, 0.83-1.10). Among initiators of DPP-4 inhibitors compared with sulfonylureas (n = 2686), the risk of hospitalization for heart failure was 1.08 (95% CI, 0.79-1.49), whereas the risk of MACEs was 0.93 (95% CI, 0.77-1.12). Lower risk of hypoglycemia (sHR, 0.36; 95% CI, 0.23-0.56) and all-cause mortality (sHR, 0.82; 95% CI, 0.76-0.90) was observed in DPP-4 initiators compared with long-acting insulin. CONCLUSIONS AND IMPLICATIONS: In residents of LTCFs receiving metformin, initiation of DPP-4 inhibitors was associated with a similar 5-year cardiovascular risk to long-acting insulin or sulfonylurea, but with a lower risk of hypoglycemia and all-cause mortality compared with long-acting insulin. These findings support the preferential use of DPP-4 inhibitors over long-acting insulin as add-on therapy to metformin in older people with diabetes in LTCFs.

doi.org/10.1016/j.jamda.2025.105911PubMed 41075820Interventions

AgingResearch.News